Yunding Shine: EVM14 Injection New Drug Clinical Trial Application Accepted

Yunding Xinyao announced today that its universal stock tumor therapeutic vaccine EVM14 Injection has officially been accepted by the Drug Evaluation Center of the National Medical Products Administration for new drug clinical trial application. EVM14 has become the company's first mRNA tumor therapeutic vaccine to achieve dual filing with both the National Medical Products Administration of China and the Food and Drug Administration of the United States. In March 2025, the new drug clinical trial application for EVM14 was approved by the Food and Drug Administration of the United States.